|
|
降糖药物对糖尿病合并慢性阻塞性肺疾病影响的研究进展
|
Abstract:
慢性阻塞性肺疾病(Chronic obstructive pulmonary disease, COPD)和2型糖尿病(type 2 diabetes, T2DM)是临床上常见的慢性疾病。相关研究发现，T2DM是COPD的重要且常见的合并症，会相互促进，加重病情。本文拟就降糖药物对糖尿病合并COPD患者预后影响的研究进展进行综述。
Chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2DM) are common chronic diseases in clinic. Relevant studies have found that T2DM is an important and common comorbidity of COPD, which will promote each other to aggravate the disease. This article will review the re-search progress of the effect of hypoglycemic drugs on the prognosis of patients with diabetes mellitus and COPD.
| [1] | 陈秀凤. 用吸入用布地奈德混悬液联合硫酸特布他林雾化液治疗慢阻肺急性加重期的效果[J]. 当代医药论丛, 2018, 16(10): 148-149. |
| [2] | Lozano, R., Naghavi, M., Foreman, K., et al. (2012) Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2095-2128. https://doi.org/10.1016/S0140-6736(12)61728-0 |
| [3] | Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (The China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717.
https://doi.org/10.1016/S0140-6736(18)30841-9 |
| [4] | Adeloye, D., Chua, S., Lee, C., et al. (2015) Global and Re-gional Estimates of COPD Prevalence: Systematic Review and Meta-Analysis. Journal of Global Health, 5, Article ID: 020415. https://doi.org/10.7189/jogh.05.020415 |
| [5] | Sun, H., Saeedi, P., Karuranga, S., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article ID: 109119. https://doi.org/10.1016/j.diabres.2021.109119 |
| [6] | 祖丽胡玛尔？阿布都艾尼, 刘超. 老年糖尿病的流行病学特点[J]. 实用老年医学, 2022, 36(10): 973-977. |
| [7] | Mirrakhimov, A.E. (2012) Chronic Obstructive Pulmonary Disease and Glucose Metabolism: A Bitter Sweet Symphony. Cardiovascular Diabetology, 11, Article No. 132. https://doi.org/10.1186/1475-2840-11-132 |
| [8] | Hotamisligil, G.S., Peraldi, P., Budavari, A., et al. (1996) IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Re-sistance. Science, 271, 665-670.
https://doi.org/10.1126/science.271.5249.665 |
| [9] | Burt, M.G., Roberts, G.W., Aguilar-Loza, N.R., Frith, P. and Stranks, S.N. (2011) Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone for COPD. The Journal of Clinical Endocrinology & Metabolism, 96, 1789-1796. https://doi.org/10.1210/jc.2010-2729 |
| [10] | Lempp, M.P., Sigler, M.A., Adesoye, A.A., Ponnuru, A. and Duval, C.E. (2022) Assessment of Glycemic Control in Veterans with Chronic Obstructive Pulmonary Disease and Type 2 Dia-betes Mellitus on Inhaled Corticosteroid Therapy. Journal of Pharmacy Practice, 35, 7-12. https://doi.org/10.1177/0897190020936870 |
| [11] | Hsu, I.-L., Lu, C.-L., Li, C.-C., et al. (2018) Population-Based Cohort Study Suggesting a Significantly Increased Risk of Developing Chronic Obstructive Pulmonary Disease in Peo-ple with Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice, 138, 66-74. https://doi.org/10.1016/j.diabres.2018.01.037 |
| [12] | Cazzola, M., Rogliani, P., Calzetta, L., Lauro, D., Page, C. and Matera, M. G. (2017) Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences, 38, 940-951.
https://doi.org/10.1016/j.tips.2017.07.003 |
| [13] | Maddatu, J., Anderson-Baucum, E. and Evans-Molina, C. (2017) Smoking and the Risk of Type 2 Diabetes. Translational Research, 184, 101-107. https://doi.org/10.1016/j.trsl.2017.02.004 |
| [14] | Larsen, S., Rab？l, R., Hansen, C.N., et al. (2012) Metfor-min-Treated Patients with Type 2 Diabetes Have Normal Mitochondrial Complex I Respiration. Diabetologia, 55, 443-449. https://doi.org/10.1007/s00125-011-2340-0 |
| [15] | Horadagoda, C., Dinihan, T., Roberts, M. and Kairaitis, K. (2017) Body Composition and Micronutrient Deficiencies in Patients with an Acute Exacerbation of Chronic Obstruc-tive Pulmonary Disease. Internal Medicine Journal, 47, 1057-1063. https://doi.org/10.1111/imj.13453 |
| [16] | Paulin, F.V., Zagatto, A.M., Chiappa, G.R. and de Tarso Müller, P. (2017) Addition of Vitamin B12 to Exercise Training Im-proves Cycle Ergometer Endurance in Advanced COPD Patients: A Randomized and Controlled Study. Respiratory Medicine, 122, 23-29. https://doi.org/10.1016/j.rmed.2016.11.015 |
| [17] | Yen, F.-S., Wei, J.C.-C., Yang, Y.-C., Hsu, C.-C. and Hwu, C.-M. (2020) Respiratory Outcomes of Metformin Use in Patients with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease. Scientific Reports, 10, Article No. 10298.
https://doi.org/10.1038/s41598-020-67338-2 |
| [18] | Tseng, C.-H. (2019) Metformin and Risk of Chronic Obstructive Pulmonary Disease in Diabetes Patients. Diabetes & Metabolism, 45, 184-190. https://doi.org/10.1016/j.diabet.2018.05.001 |
| [19] | Ho, T.-W., Huang, C.-T., Tsai, Y.-J., et al. (2019) Metformin Use Mitigates the Adverse Prognostic Effect of Diabetes Mellitus in Chronic Obstructive Pulmonary Disease. Respira-tory Research, 20, Article No. 69.
https://doi.org/10.1186/s12931-019-1035-9 |
| [20] | Kim, H.J., Lee, J.Y., Jung, H.S., et al. (2010) The Impact of Insu-lin Sensitisers on Lung Function in Patients with Chronic Obstructive Pulmonary Disease and Diabetes. The Internation-al Journal of Tuberculosis and Lung Disease, 14, 362-367. |
| [21] | Lea, S., Plumb, J., Metcalfe, H., et al. (2014) The Ef-fect of Peroxisome Proliferator-Activated Receptor-γ Ligands on in Vitro and in Vivo Models of COPD. European Res-piratory Journal, 43, 409-420.
https://doi.org/10.1183/09031936.00187812 |
| [22] | Khateeb, J., Fuchs, E. and Khamaisi, M. (2019) Diabetes and Lung Disease: An Underestimated Relationship. Review of Diabetic Studies, 15, 1-15. https://doi.org/10.1900/RDS.2019.15.1 |
| [23] | Tseng, C.H. (2022) Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease, 17, 285-295.
https://doi.org/10.2147/COPD.S345796 |
| [24] | Yen, F.-S., Wei, J.C.-C., Yang, Y.-C., Hsu, C.-C. and Hwu, C.-M. (2021) Thiazolidinedione Use in Individuals with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease. Fron-tiers in Medicine, 8, Article 729518.
https://doi.org/10.3389/fmed.2021.729518 |
| [25] | Guardado-Mendoza, R., Prioletta, A., Jiménez-Ceja, L.M., Sosale, A. and Folli, F. (2013) State of the Art Paper: The Role of Nateglinide and Repaglinide, Derivatives of Meglitinide, in the Treatment of Type 2 Diabetes Mellitus. Archives of Medical Science, 5, 936-943. https://doi.org/10.5114/aoms.2013.34991 |
| [26] | Ballmann, M., Hubert, D., Assael, B.M., et al. (2018) Repaglinide versus Insulin for Newly Diagnosed Diabetes in Patients with Cystic Fibrosis: A Multicentre, Open-Label, Randomised Trial. The Lancet Diabetes and Endocrinology, 6, 114-121. https://doi.org/10.1016/S2213-8587(17)30400-X |
| [27] | Rutten, E.P., Lenaerts, K., Buurman, W.A. and Wouters, E.F. (2014) Disturbed Intestinal Integrity in Patients with COPD. CHEST, 145, 245-252. https://doi.org/10.1378/chest.13-0584 |
| [28] | Sun, Y., Zheng, F., Li, Y., et al. (2013) Correlation between Lower Gastrointestinal Tract Symptoms and Quality of Life in Patients with Stable Chronic Obstructive Pulmonary Disease. Journal of Traditional Chinese Medicine, 33, 608-614. https://doi.org/10.1016/S0254-6272(14)60029-7 |
| [29] | Hancu, A. (2019) Nutritional Status as a Risk Factor in COPD. Maedica, 14, 140-143. |
| [30] | Wu, S.-W., Ho, Y.-C., Luo, C.-W., et al. (2021) Oral Treatment for Diabetes Us-ing α-Glucosidase Inhibitors Was a Risk Factor for Chronic Obstructive Pulmonary Disease: A Cohort Study. Interna-tional Journal of Medical Sciences, 18, 778-784. https://doi.org/10.7150/ijms.55361 |
| [31] | Viby, N.-E., Isidor, M.S., Buggeskov, K.B., et al. (2013) Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice. Endocrinology, 154, 4503-4511. https://doi.org/10.1210/en.2013-1666 |
| [32] | Huang, J., Yi, H., Zhao, C., et al. (2018) Glucagon-Like Peptide-1 Re-ceptor (GLP-1R) Signaling Ameliorates Dysfunctional Immunity in COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease, 13, 3191- 3202. https://doi.org/10.2147/COPD.S175145 |
| [33] | Oztay, F., Sancar-Bas, S., Gezginci-Oktayoglu, S., Ercin, M. and Bolkent, S. (2018) Exendin-4 Partly Ameliorates- Hyperglyce-mia-Mediated Tissue Damage in Lungs of Streptozotocin-Induced Diabetic Mice. Peptides, 99, 99-107.
https://doi.org/10.1016/j.peptides.2017.12.007 |
| [34] | Shao, S., Xu, Q., Yu, X., Pan, R. and Chen, Y. (2020) Dipep-tidyl Peptidase 4 Inhibitors and Their Potential Immune Modulatory Functions. Pharmacology & Therapeutics, 209, Ar-ticle ID: 107503.
https://doi.org/10.1016/j.pharmthera.2020.107503 |
| [35] | Klemann, C., Wagner, L., Stephan, M. and von H？rsten, S. (2016) Cut to the Chase: A Review of CD26/Dipeptidyl Peptidase-4’s (DPP4) Entanglement in the Immune System. Clinical and Experimental Immunology, 185, 1-21.
https://doi.org/10.1111/cei.12781 |
| [36] | Meyerholz, D.K., Lambertz, A.M. and McCray, P.B. (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract. The American Journal of Pathology, 186, 78-86. https://doi.org/10.1016/j.ajpath.2015.09.014 |
| [37] | Somborac-Ba？ura, A., Buljevi？, S., Rumora, L., et al. (2012) De-creased Soluble Dipeptidyl Peptidase IV Activity as a Potential Serum Biomarker for COPD. Clinical Biochemistry, 45, 1245-1250.
https://doi.org/10.1016/j.clinbiochem.2012.04.023 |
| [38] | Seys, L.J.M., Widagdo, W., Verhamme, F.M., et al. (2018) DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, Is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clinical Infectious Diseases, 66, 45-53. https://doi.org/10.1093/cid/cix741 |
| [39] | Gerards, M.C., Venema, G.E., Patberg, K.W., et al. (2018) Dapagliflozin for Prednisone-Induced Hyperglycaemia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Diabetes, Obesity and Metabolism, 20, 1306-1310.
https://doi.org/10.1111/dom.13209 |
| [40] | Pradhan, R., Lu, S., Yin, H., et al. (2022) Novel Antihyperglycaemic Drugs and Prevention of Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes: Population Based Cohort Study. BMJ, 379, e071380. https://doi.org/10.1136/bmj-2022-071380 |
